10-Q: Structure Therapeutics Q3: Losses Mount, Clinical Pipeline Advances

Structure Therapeutics reports increased net losses in Q3 2025, driven by higher R&D, while advancing its obesity and IPF clinical programs and securing additional capital.

Summary

• Net loss for the three months ended September 30, 2025, was $65.7 million, compared to $34.0 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $174.2 million, compared to $86.0 million for the same period in 2024.
• Accumulated deficit as of September 30, 2025, reached $503.3 million.
• Cash, cash equivalents, and short-term investments totaled $799.0 million as of September 30, 2025, projected to fund operations through at least 2027, excluding Phase 3 registrational studies for aleniglipron.
• Research and development expenses increased by 81% to $59.0 million for Q3 2025 and by 108% to $156.6 million for the nine months ended September 30, 2025, primarily due to clinical trial costs, preclinical R&D, and increased personnel.
• Enrollment was completed in February 2025 for the Phase 2b ACCESS and ACCESS II studies of aleniglipron (GLP-1R agonist for obesity), with topline data expected by year-end 2025.
• Multiple new aleniglipron studies were announced in August 2025, including an open-label extension to ACCESS, an extension to ACCESS II (to 44 weeks), a maintenance switching study, a body fat loss study (DEXA), and a study in patients with obesity and type 2 diabetes mellitus (T2DM).
• ACCG-2671, a dual amylin calcitonin receptor agonist (DACRA), is advancing with IND-enabling activities ongoing and a first-in-human Phase 1 clinical study expected by year-end 2025, supported by positive preclinical data.
• ACCG-3535 was selected as a second DACRA development candidate in November 2025, showing robust food intake suppression and significant body weight reduction in preclinical studies.
• The Phase 1 clinical study of LTSE-2578 (LPA1R antagonist for idiopathic pulmonary fibrosis) was completed in July 2025, demonstrating favorable safety and tolerability.
• ANPA-0073 (APJ receptor agonist) is Phase 2 ready and undergoing long-term GLP-toxicology studies, expected to be completed in 2025.
• The company sold 3,040,000 American Depositary Shares (ADSs) under an At-the-Market (ATM) Sales Agreement in September 2025, generating net proceeds of $55.8 million, with $191.5 million remaining available under the agreement.
• A subsidiary, Basecamp Bio Inc., entered an asset purchase agreement with Exelixis, Inc. in August 2025 for early-stage non-metabolic and non-obesity assets, with potential for $10.0 million in initial payments ($5.2 million received) and up to $90.0 million in milestone payments, plus low single-digit royalties.
• A $3.0 million milestone payment was achieved and paid under the Aconcagua-Schrdinger Agreement as of September 30, 2025.

Sentiment

Score: 6

Explanation: While financial losses are increasing significantly due to R&D investments, the company is actively advancing a broad pipeline of product candidates with positive early clinical and preclinical data, and has secured substantial funding to support operations for the next two years, indicating strategic progress despite current unprofitability.

Positives

• Completed enrollment for Phase 2b ACCESS and ACCESS II studies for aleniglipron, with topline data anticipated by year-end 2025.
• Initiated multiple new aleniglipron studies, including an open-label extension, an extension to ACCESS II, a maintenance switching study, a body fat loss study, and a T2DM study, to strengthen its competitive positioning and support Phase 3 design.
• Advanced the amylin receptor agonist program with ACCG-2671 as a lead development candidate, with a first-in-human Phase 1 clinical study expected by year-end 2025, supported by positive preclinical data showing significant weight reductions.
• Selected ACCG-3535 as a second DACRA development candidate, demonstrating high binding affinity and robust food intake suppression in preclinical studies.
• Successfully completed the Phase 1 study for LTSE-2578 (IPF), showing no dose-dependent adverse events and generally favorable safety and tolerability.
• ANPA-0073 is Phase 2 ready and progressing through GLP-toxicology studies.
• Maintained a strong cash, cash equivalents, and short-term investments balance of $799.0 million, providing a projected funding runway through at least 2027 for current operations (excluding Phase 3 aleniglipron studies).
• Successfully raised $55.8 million in net proceeds through an At-the-Market (ATM) Offering in September 2025, enhancing liquidity.
• Entered into an asset purchase agreement with Exelixis, Inc., providing potential for $10.0 million in initial payments and up to $90.0 million in milestone payments, plus royalties.
• Remediated a previously reported material weakness in internal control over financial reporting as of June 30, 2024.

Negatives

• Net loss significantly increased to $65.7 million for Q3 2025, up from $34.0 million in Q3 2024, and to $174.2 million for the nine months ended September 30, 2025, up from $86.0 million in the prior year.
• Accumulated deficit grew to $503.3 million as of September 30, 2025, reflecting ongoing unprofitability.
• Research and development expenses more than doubled for the nine-month period, contributing to the increased net losses.
• Interest and other income, net, decreased for Q3 2025 to $8.2 million from $12.0 million in Q3 2024, primarily due to lower cash balances and interest rates.
• The company has no products approved for commercial sale and has not generated any significant product revenue to date.
• Substantial additional capital will be required to fund Phase 3 clinical studies of aleniglipron and future operations, which may not be available on acceptable terms or at all.

Risks

• Limited operating history and significant operating losses since inception, with expectations of continued losses for the foreseeable future.
• Requirement for substantial additional capital to finance operations, which may not be available on acceptable terms, or at all, potentially forcing delays, limits, or termination of product development programs.
• The approach to product candidate discovery based on the technology platform is unproven, with no guarantee of developing commercially valuable products.
• Early stage of development for all product candidates; inability to advance them in clinical development, obtain regulatory approval, or commercialize them could materially harm the business.
• Clinical and preclinical drug development is a lengthy, expensive, and uncertain process, and prior results are not necessarily predictive of future outcomes.
• Difficulties or delays in the commencement or completion, or termination or suspension, of planned clinical studies could result in increased costs, delay revenue generation, and adversely affect commercial prospects.
• Serious adverse events, undesirable side effects, or other unexpected properties of product candidates may be identified during development or after approval, leading to discontinuation, refusal of approval, or revocation of marketing authorizations.
• Lack of organizational experience in conducting later-stage clinical studies or submitting New Drug Applications (NDAs).
• The marketing approval processes of the U.S. Food and Drug Administration (FDA) and foreign authorities are lengthy, time-consuming, expensive, and inherently unpredictable.
• The FDA and other foreign equivalents may not accept data from clinical studies conducted outside the United States, potentially delaying development plans.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business, financial condition, results of operations, and prospects.
• Disruptions to the operations of the FDA, SEC, or comparable foreign regulatory authorities caused by funding shortages, leadership changes, or staffing cuts could materially and adversely affect the business.
• Reliance on third parties for the manufacture of product candidates increases the risk of insufficient quantities, unacceptable cost, or quality, which could delay or impair development or commercialization efforts.
• Current and anticipated future dependence upon others for manufacturing may adversely affect future profit margins and ability to commercialize products on a timely and competitive basis.
• Reliance on third parties to conduct, supervise, and monitor discovery research, preclinical studies, and clinical studies; past delays due to third-party actions.
• Collaboration agreements and strategic alliances may not realize anticipated benefits, and the company may be unable to form future collaborations or realize their potential benefits.
• Existing discovery collaborations with Schrdinger are important, and inability to maintain them or their lack of success could adversely affect the business.
• Substantial competition from other companies, including those utilizing AI and other computational approaches for drug discovery.
• No marketing and sales organization; significant resources needed to develop these capabilities or reliance on third parties.
• Operations through Australian wholly-owned subsidiaries are subject to risks of losing ability to operate or inability to receive research and development tax credits.
• Changes in political and economic policies or relations between China and the United States may affect business, financial condition, results of operations, and the market price of ADSs.
• Inability to obtain and maintain sufficient intellectual property protection for platform technologies and product candidates, or if the scope is not sufficiently broad, competitors could develop similar products.
• Reliance on one or more in-licenses from third parties; loss of these rights or disputes with licensors could materially adversely affect the business.
• Preliminary, topline, and interim data from clinical studies may change as more patient data become available and are subject to audit and verification procedures.
• Obtaining and maintaining marketing approval in one jurisdiction does not guarantee success in other jurisdictions.
• Market opportunities for product candidates may be smaller than estimated, adversely affecting revenue.
• Ongoing regulatory obligations and continued regulatory review post-approval may result in significant additional expense, labeling restrictions, or market withdrawal.
• Failure of approved product candidates to achieve market acceptance by physicians, patients, third-party payors, or others in the medical community.
• Coverage and adequate reimbursement may not be available for product candidates, making profitable sales difficult.
• Product liability lawsuits could cause substantial liabilities and limit commercialization.
• Compromised information technology systems or data security incidents could lead to significant financial, legal, regulatory, business, and reputational harm.
• Employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities.
• Governments outside the United States tend to impose strict price controls, which may adversely affect revenues.
• Subject to stringent and evolving U.S. and foreign laws, regulations, rules, industry standards, contractual obligations, policies, and other obligations related to data security and privacy (e.g., HIPAA, CCPA, GDPR, PIPL).
• Tax risk associated with the reporting of cross-border arrangements and activities between the company and its subsidiaries.
• Classification as a China resident enterprise for China income tax purposes could result in unfavorable tax consequences.
• Uncertainties in China with respect to indirect transfers of equity interests in China resident enterprises.
• Failure to comply with Chinese regulations regarding the registration requirements for employee equity incentive plans may subject the company to fines and sanctions.
• Business is subject to economic, political, regulatory, and other risks associated with international operations, particularly in China.
• Failure to comply with Chinese environmental, health, and safety laws and regulations could result in fines or penalties.
• Development in the Chinese legal system could materially and adversely affect the company.
• Exposure to liabilities under the U.S. Foreign Corrupt Practices Act (FCPA), U.S. domestic bribery laws, and similar anti-corruption and anti-bribery laws of China and other countries.
• Regulatory requirements on currency exchange may limit the ability to receive and use effectively financing in foreign currencies.
• Chinese regulations relating to the establishment of offshore special purpose companies by residents in China may subject beneficial owners or wholly foreign-owned subsidiaries to liability or penalties.
• Patent terms may be inadequate to protect the competitive position on product candidates for an adequate amount of time.
• Intellectual property rights do not necessarily address all potential threats to the business.
• Third parties may initiate legal proceedings alleging infringement, misappropriation, or other violation of their intellectual property rights.
• Lawsuits to protect or enforce patents or other intellectual property could be expensive, time-consuming, and unsuccessful.
• Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents.
• Inability to protect intellectual property rights throughout the world.
• Claims that employees, consultants, or advisors have wrongfully used or disclosed trade secrets or other confidential information of their current or former employers.
• Failure to identify relevant third-party patents or incorrect interpretation of their relevance, scope, or expiration.
• Inadequate protection of trademarks and trade names.
• The price of ADSs may be volatile, and investors could lose all or part of their investment.
• There is no guarantee that future audit reports will be prepared by auditors subject to inspection by the Public Company Accounting Oversight Board (PCAOB), potentially limiting access to U.S. capital markets or leading to delisting under the HFCA Act.
• Identified material weaknesses in internal control over financial reporting in the past and risk of future weaknesses or failure to maintain effective internal control.
• Principal shareholders and management own a significant percentage of voting securities, enabling them to exert significant control over matters subject to shareholder approval.
• Substantial future sales of ADSs could cause the market price to drop significantly.
• Holders of ADSs have fewer rights than ordinary shareholders and must act through the depositary to exercise their rights.
• ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement.
• May not receive distributions on ordinary shares represented by ADSs if it is illegal or impractical to make them available.
• Right to participate in any future rights offerings may be limited, causing dilution.
• No cash dividends anticipated in the foreseeable future; capital appreciation is the sole source of gains.
• Subject to tax in both the Cayman Islands and the United States.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited.
• Significantly increased costs and management time due to operating as a public company.
• Disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
• Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations.
• If equity research analysts do not publish research or publish unfavorable reports, the price and trading volume of ADSs could decline.
• Could be subject to securities class action litigation or material legal proceedings.
• Adversely affected by earthquakes, fires, or other natural disasters, with potentially inadequate business continuity and disaster recovery plans.
• Failure to meet Nasdaq's continued listing requirements could result in a delisting of ADSs.

Future Outlook

The company expects to incur significant and increasing expenses and operating losses for the foreseeable future as it advances its research and development activities, expands its product pipeline, hires additional personnel, and seeks regulatory approvals. Current cash, cash equivalents, and short-term investments are projected to fund operations and key clinical milestones through at least 2027, but this estimate excludes funding for Phase 3 registrational studies of aleniglipron, for which substantial additional capital will be required. Topline data from the ACCESS and ACCESS II studies for aleniglipron, and the initiation of a first-in-human Phase 1 clinical study for ACCG-2671, are expected by year-end 2025. GLP-toxicology studies for ANPA-0073 are also expected to be completed in 2025.

Management Comments

• We are a clinical stage global biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical need.
• Our differentiated technology platform leverages both structure-based drug discovery and our expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs).
• Our product candidates, as oral small molecules, have the potential to be more accessible medicines than biologics and peptide therapies with potentially differentiated efficacy and safety and, from a manufacturing standpoint, more scalable towards meeting global demand.
• Based on our current business plan, we estimate that our existing cash, cash equivalents and short-term investments will be sufficient to fund our projected operations and key clinical milestones through at least 2027. For aleniglipron, this includes costs related to the ongoing ACCESS and ACCESS II studies, extension studies, the supplementary studies, and Phase 3 readiness activities, but excludes Phase 3 registrational studies.
• We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, particularly if and as we continue to invest in our research and development activities and initiate additional clinical studies, expand our product pipeline, hire additional personnel and invest in and grow our business, maintain, expand and protect our intellectual property portfolio, and seek regulatory approvals for and commercialize any approved product candidates.
• We will need substantial additional capital to develop our product candidates, including to fund Phase 3 clinical studies of aleniglipron, and fund operations for the foreseeable future.

Industry Context

The company operates in the highly competitive and rapidly evolving biopharmaceutical industry, focusing on G-protein coupled receptors (GPCRs), which are targets for a significant portion of marketed medicines. Its lead candidate, aleniglipron, is an oral small molecule GLP-1R agonist, positioning it in a competitive landscape against established injectable GLP-1R peptides (e.g., Novo Nordisk, Eli Lilly) and a growing number of other oral small molecules from various pharmaceutical and biotechnology companies. The company's strategy emphasizes oral small molecules for their potential accessibility, differentiated efficacy/safety, and manufacturing scalability compared to biologics and peptides. The filing also acknowledges increasing competition from companies leveraging AI and computational approaches for drug discovery, a trend that could impact the effectiveness of its own platform.

Comparison to Industry Standards

• Aleniglipron's Phase 2a obesity study demonstrated a placebo-adjusted mean weight decrease of 6.2% at 12 weeks (capsule formulation) and up to 6.9% (tablet formulation), which are key efficacy metrics in the GLP-1R agonist space.
• Preclinical data for ACCG-2671 and ACCG-3535 showed significant, dose-dependent body weight reductions and superior weight loss when combined with semaglutide, indicating potential competitive efficacy against a leading GLP-1R agonist.
• The company notes that the preliminary nature, study length, and sample size of its aleniglipron results may limit direct comparability to other weight loss products or candidates, including other oral selective GLP-1RAs, suggesting a cautious approach to competitive claims at this stage.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently the subject of any material governmental investigation, private lawsuit, or other legal proceeding.
• May be involved in legal and regulatory proceedings or investigations in the ordinary course of business in the future, which could result in significant fines or penalties, adverse impact on reputation, business, and financial condition, or diversion of management attention.

Related Party Transactions

• Lhotse Bio, Inc. (wholly-owned subsidiary) has a collaboration agreement (Lhotse-Schrdinger Agreement) with Schrdinger LLC (a shareholder) since October 2020 to discover and develop LPA1R inhibitors. Payments to Schrdinger LLC totaled $0.8 million as of December 31, 2024. Potential development and regulatory milestone payments up to $17.0 million and low single-digit royalties are outlined.
• Aconcagua Bio, Inc. (wholly-owned subsidiary) has a collaboration agreement (Aconcagua-Schrdinger Agreement) with Schrdinger, Inc. since November 2023 to discover and develop small molecule modulators of a specific target. Monthly active program payments are in the low six digits. Potential development, regulatory, and commercialization milestone payments up to $89.0 million for the first product and low single-digit royalties are outlined.
• As of September 30, 2025, one milestone of $3.0 million was achieved and paid under the Aconcagua-Schrdinger Agreement.
• Ramy Farid, the President and Chief Executive Officer of Schrdinger, Inc., was a member of the company's board of directors until June 25, 2024, at which time he ceased being a related party.

Stakeholder Impact

• **Shareholders:** Face potential dilution from future equity offerings, volatility in ADS price, and rely solely on capital appreciation as no dividends are anticipated. ADS holders have fewer rights than ordinary shareholders and may not be entitled to a jury trial for certain claims. There is a risk of delisting if the HFCA Act applies due to auditor inspection issues, though currently deemed remote.
• **Employees:** The company expects to increase headcount, particularly in clinical development, discovery, manufacturing, and administrative functions. Employees participate in share-based compensation plans (ESPP, restricted share units) and are subject to confidentiality and non-compete obligations.
• **Customers/Patients:** The company aims to develop novel oral therapeutics for chronic diseases with unmet medical needs (e.g., obesity, T2DM, IPF), potentially offering more accessible medicines than existing biologics and peptide therapies.
• **Suppliers/Creditors:** The company's reliance on third-party manufacturers, particularly in China, introduces supply chain risks, including potential impacts from international trade policies. The need for substantial additional financing could affect creditors.
• **Regulatory Bodies:** The company is subject to extensive and evolving regulations from the FDA, SEC, and foreign authorities, as well as data privacy laws (HIPAA, CCPA, GDPR, PIPL), incurring significant compliance costs and risks.

Next Steps

• Report topline data from Phase 2b ACCESS and ACCESS II studies for aleniglipron by year-end 2025.
• Initiate a first-in-human Phase 1 clinical study for ACCG-2671 by year-end 2025.
• Complete long-term GLP-toxicology studies for ANPA-0073 in 2025.
• Continue to invest in research and development activities and initiate additional clinical studies.
• Expand the product pipeline and hire additional personnel.
• Maintain, expand, and protect the intellectual property portfolio.
• Seek regulatory approvals for and commercialize any approved product candidates.
• Seek substantial additional capital to fund Phase 3 clinical studies of aleniglipron and future operations.
• Evaluate manufacturing strategy to satisfy demand for registration studies and commercial products.
• Monitor geopolitical and macroeconomic factors for potential impacts on business.
• Evaluate the impact of new accounting standards (ASU 2023-09, ASU 2024-03) on financial disclosures.

Key Dates

Recommendation

The company is in a high-growth, high-risk clinical stage, characterized by significant R&D investments leading to substantial net losses. While the financial performance shows increasing losses, this is expected for a biopharmaceutical company advancing multiple product candidates through clinical trials. The positive progress in the aleniglipron program (completion of Phase 2b enrollment, initiation of new studies) and the advancement of other pipeline candidates (ACCG-2671, ACCG-3535, LTSE-2578, ANPA-0073) are encouraging. The company has a strong cash position ($799.0 million) providing runway through at least 2027 for current plans, and has successfully raised additional capital through an ATM offering. However, the explicit need for 'substantial additional capital' for Phase 3 aleniglipron studies and future operations, coupled with geopolitical and regulatory risks, suggests continued financial uncertainty. The stock is likely to remain volatile, driven by clinical trial readouts and future financing events. A 'Hold' recommendation reflects the balance between promising pipeline developments and the inherent financial risks and capital requirements of a clinical-stage biopharma company.

Keywords

Biopharmaceutical, GLP-1R agonist, Obesity, Type 2 Diabetes, Idiopathic Pulmonary Fibrosis, Amylin Receptor Agonist, DACRA, APJ Receptor Agonist, Clinical Stage, Drug Discovery, SEC Filing, 10-Q, Structure Therapeutics, Aleniglipron, ACCG-2671, ACCG-3535, LTSE-2578, ANPA-0073, Research and Development, Financial Results, Capital Raise, Clinical Trials, Preclinical Development, Intellectual Property, Corporate Governance, China Operations, Biotechnology